XTANDI + Leuprolide combo Significantly Improves Survival Outcomes in Men with Non-Metastatic HSPC with High-Risk Biochemical Recurrence July 15, 2025
FDA Grants Fast Track Designation for TRE-515 in Combination with Radiation Therapy for the Treatment of Metastatic CRPC July 15, 2025
Recruitment Initiated into Expanded Ph 2 Opaganib/Darolutamide Combo Study in Advanced Prostate Cancer July 8, 2025
Submission of extension of indication application to EMA of AKEEGA with prednisone or prednisolone for mHSPC and HRR gene alterations announced July 8, 2025
Confirmatory Ph 3 trial of masitinib in metastatic CRPC authorized by FDA and EMA, with biomarker to target patients with less advanced metastatic disease July 8, 2025
Preliminary data announced for gedatolisib from Ph 1 CELC-G-201 trial in metastatic CRPC and Ph 2 HER2+ metastatic breast cancer patients July 1, 2025
ATNM-400 Demonstrates Superior Efficacy to Enzalutamide and Ability to Overcome Resistance to ARPI and PSMA-Ac-225/Lu-177 Labelled Radiotherapy in Prostate Cancer July 1, 2025
Update on U.S. Regulatory Review of TALZENNA in Combination with XTANDI for Broader Use in Metastatic CRPC Provided June 25, 2025
IDeate-Prostate01 Ph 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Pretreated Metastatic CRPC June 24, 2025
FDA clears IND application for ART-101 for the imaging and treatment of prostate cancer June 24, 2025
Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3 to RayzeBio, a BMS Company, for a potential value of up to $1.35B plus royalties June 17, 2025
AKEEGA® (niraparib and abiraterone acetate dual-action tablet) improved efficacy in patients with HRR-mutated mHSPC vs. current SoC June 11, 2025
FDA grants Regenerative Medicine Advanced Therapy (RMAT) Designation for CAN-2409 for the Treatment of Prostate Cancer June 3, 2025
Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA+ve metastatic HSPC June 3, 2025
Archeus Technologies and Wisconsin Alumni Research Foundation to Advance ART-101 into Clinical Development for Prostate Cancer May 26, 2025
Successful End of Ph 2 Meeting with US FDA on Ph 3 Registrational Study Design for PT-112 in Patients with Metastatic CRPC Announced May 21, 2025
Ph 2 Trial evaluating the efficacy and safety of Lutetium (177Lu) rhPSMA-10.1 Injection initiated in metastatic CRPC May 13, 2025
CAPItello-280 Ph 3 trial of Truqap (capivasertib) + docetaxel and ADT in patients with metastatic CRPC to be discontinued May 6, 2025
FDA approves Pluvicto for earlier use before chemotherapy in PSMA-positive metastatic CRPC April 2, 2025
US FDA grants Fast Track Designation to Cu-67 SAR-bisPSMA for the treatment of metastatic CRPC patients February 25, 2025
